Survival outcomes with carboplatin versus cisplatin and the impact of COVID-19 on platinum choice: A nationwide Netherlands registry study in small cell lung cancer patients (CACIS)
These findings challenge the long-standing belief of cisplatin's superiority and support the adoption of carboplatin in SCLC.
Authors
- Chris Dickhoff (ORCID: https://orcid.org/0000-0002-6396-8372)
- Famke L. Schneiders (ORCID: https://orcid.org/0000-0002-5204-1774)
- Ilias Houda (ORCID: https://orcid.org/0000-0002-8216-5268)
- Nicole P. Barlo
- Teodora Radonic (ORCID: https://orcid.org/0000-0002-6015-5202)
- R. Shaikh (ORCID: https://orcid.org/0009-0008-7206-654X)
- Birgit I. Lissenberg‐Witte (ORCID: https://orcid.org/0000-0001-9448-1826)
- Ezgi B Ulas (ORCID: https://orcid.org/0000-0003-1551-738X)
- Elisabeth A. Kastelijn (ORCID: https://orcid.org/0000-0001-8954-2452)
- Idris Bahce (ORCID: https://orcid.org/0000-0002-1111-608X)
- Suresh Senan (ORCID: https://orcid.org/0000-0003-3995-2204)
- D.D. Naves (ORCID: https://orcid.org/0000-0001-7344-2414)
- Ronald Damhuis (ORCID: https://orcid.org/0000-0001-7248-7047)
- Hicham Bouhaddou
Institutions
- Noordwest Ziekenhuisgroep (NL)
- St. Antonius Ziekenhuis (NL)
- Amsterdam Neuroscience (NL)
- Netherlands Comprehensive Cancer Organisation (NL)
- Amsterdam University Medical Centers (NL)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-10-04
- DOI
- https://doi.org/10.1016/j.ejca.2025.116042
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00